A Phase 1 interventional study of Pegylated Recombinant Candida Utilis Uricase for Injection in Gout and Hyperuricemia, sponsored by Shenyang Sunshine Pharmaceutical Co., LTD.. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-05-28.
Sponsored by Shenyang Sunshine Pharmaceutical Co., LTD. (part of 3SBio Inc.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies in Gout with a site in China — 11 open to participants now, 15 under way, 2 of them phase 3. Gout · China.
Among the 49 studies in Gout with a site in China, this one is the 29th largest by planned enrollment of the 44 interventional ones that give a count, is one of 7 that started in 2023, is one of 16 in phase 1, reaches primary completion later than 7 of the 14 other live ones, and was the 35th registered.
347 studies on the registry are indexed under Gout; 50 are open to participants now.
Browse Gout studies →11 of the 49 studies in Gout with a site in China are open now. Recruiting first, the newest first:
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18–75
Huashan Hospital · Sites in China
Ages 18–70
Shanghai Institute Of Biological Products · Sites in China
Ages 18–70
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–70
The Affiliated Hospital of Inner Mongolia Medical University · Sites in China
Ages 18–70
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 31 Gout studies recruiting now, 14 (45%) set no upper age limit and 10 (32%) stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 9 · Phase 3 10 · Phase 4 3
First in 2010; this study’s year is marked. 7 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 83 across 288 interventional studies indexed under Gout.
Median enrollment 93 across the 44 interventional studies, 350 across the 5 observational. Of the 25 that completed or were terminated, 3 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 49 have an industry lead sponsor. The 10 most frequent:
This study is registered under Shenyang Sunshine Pharmaceutical Co., LTD., one of the names counted as 3SBio Inc.. Under that name alone:
Shenyang Sunshine Pharmaceutical Co., LTD. is the lead sponsor of 40 studies on the registry; 22 are open to participants now.
3SBio Inc. has 5 studies filed under Gout — fewer than ten, so there is no comparison to draw.
5 of the studies in Gout with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07414394Phase 3Innovent Biologics Technology Limited (Shanghai R&D Center)Tigulixostat (IBI128) vs Febuxostat in Gout | 2027-04-30 |
| NCT06629376Shenyang Sunshine Pharmaceutical Co., LTD.Safety, Tolerability, and Pharmacokinetic Characteristics of SSS11 in Patients With Gout and Hyperuricemia | 2026-12-20 |
| NCT06298071Shanghai Institute Of Biological ProductsA Phase Ib Clinical Trial of Peguricase for Injection With Methotrexate in Patients With Uncontrolled Gout. | 2026-12-30 |
| NCT07587684Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyA Study of IN026 in Participants With Refractory Gout | 2027-08 |
| NCT07326839XueMei GuoOrlistat and Weight Management for Uric Acid Control in Obese Gout: A RCT | 2027-11-09 |
Add all 5 to your calendar (.ics) → With an account.
Among the 49 studies in Gout with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a safety, tolerability, pharmacokinetics, and preliminary pharmacological study of multiple administration, dose escalation, randomized double-blind, placebo-controlled.The main purpose of this experiment is to evaluate the safety and tolerability of multiple injections of PEGylated recombinant Candida urate oxidase (test drug code: SSS11) in patients with gout and hyperuricemia.The experimental period includes a screening period of 4 weeks, a treatment period of 4 or 8 weeks, and an observation period of 4 weeks。
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
injection;strength;4mg
Drug: Pegylated Recombinant Candida Utilis Uricase for Injection
injection;strength;8mg
Drug: Pegylated Recombinant Candida Utilis Uricase for Injection
injection;strength;12mg
Drug: Pegylated Recombinant Candida Utilis Uricase for Injection
injection;strength;16mg
Drug: Pegylated Recombinant Candida Utilis Uricase for Injection
injection;strength;20mg
Drug: Pegylated Recombinant Candida Utilis Uricase for Injection
The same volume of placebo as SSS11
Drug: Pegylated Recombinant Candida Utilis Uricase for Injection
According to the dosage requirements of each experimental group, intravenous infusion should be administered for at least 2 hours each time
Also known as: SSS11
The primary outcome was safety.
Assessment AEs by frequency and severity
Time frame: up to 12 weeks
Difference between post administration blood uric acid and baseline
Time frame: up to 12 weeks
Duration of blood uric acid<360 μ mol/L
Time frame: up to 12 weeks
Proportion of subjects with blood uric acid levels below 360 μ mol/L at each sample collection time point
Time frame: up to 12 weeks
Started Nov 2023 (actual). Primary completion is estimated for Dec 2026, 37 months after the start.
Of 37 industry-sponsored phase 1 interventional studies under Gout, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 14. This study's planned 37 months is above that.
Counting every sponsor, half of 41 studies reached it within 6 months; a quarter within 2 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shenyang Sunshine Pharmaceutical Co., LTD. →